Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $60,000.00 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Sharon Townson sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $20.00, for a total transaction of $60,000.00. Following the sale, the insider owned 67,845 shares of the company’s stock, valued at $1,356,900. This trade represents a 4.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Sharon Townson also recently made the following trade(s):

• On Wednesday, June 17th, Sharon Townson sold 3,000 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $19.00, for a total transaction of $57,000.00.

Monte Rosa Therapeutics Price Performance

Shares of Monte Rosa Therapeutics stock opened at $22.28 on Friday. Monte Rosa Therapeutics, Inc. has a 1-year low of $4.12 and a 1-year high of $25.77. The company’s fifty day simple moving average is $18.96 and its 200-day simple moving average is $18.63. The stock has a market capitalization of $1.88 billion, a PE ratio of -15.05 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The company had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. As a group, research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Institutional Trading of Monte Rosa Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC purchased a new position in Monte Rosa Therapeutics in the 4th quarter worth approximately $30,000. Russell Investments Group Ltd. purchased a new stake in Monte Rosa Therapeutics during the 3rd quarter valued at approximately $32,000. Lazard Asset Management LLC raised its position in shares of Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after buying an additional 3,262 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after buying an additional 451 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after buying an additional 776 shares in the last quarter. Institutional investors own 79.96% of the company’s stock.

Analyst Ratings Changes

GLUE has been the topic of a number of analyst reports. Guggenheim lowered their price objective on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. JPMorgan Chase & Co. increased their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Wells Fargo & Company dropped their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $32.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.